NYSEAMERICAN:CATX Perspective Therapeutics (CATX) Stock Price, News & Analysis $3.18 -0.04 (-1.09%) As of 01:06 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Perspective Therapeutics Stock (NYSEAMERICAN:CATX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CATX alerts:Sign Up Key Stats Today's Range$3.13▼$3.2550-Day Range$2.82▼$3.6352-Week Range$1.96▼$6.16Volume320,558 shsAverage Volume2.31 million shsMarket Capitalization$363.57 millionP/E RatioN/ADividend YieldN/APrice Target$11.56Consensus RatingModerate Buy Company Overview Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington. Read More Perspective Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreCATX MarketRank™: Perspective Therapeutics scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingPerspective Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialPerspective Therapeutics has a consensus price target of $11.56, representing about 262.8% upside from its current price of $3.19.Amount of Analyst CoveragePerspective Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Perspective Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Perspective Therapeutics are expected to decrease in the coming year, from ($1.05) to ($1.13) per share.Price to Book Value per Share RatioPerspective Therapeutics has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.22% of the float of Perspective Therapeutics has been sold short.Short Interest Ratio / Days to CoverPerspective Therapeutics has a short interest ratio ("days to cover") of 25.65, which indicates bearish sentiment.Change versus previous monthShort interest in Perspective Therapeutics has recently increased by 3.03%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPerspective Therapeutics does not currently pay a dividend.Dividend GrowthPerspective Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.64 News SentimentPerspective Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Perspective Therapeutics this week, compared to 4 articles on an average week.Search Interest14 people have searched for CATX on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.MarketBeat Follows4 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Perspective Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.99% of the stock of Perspective Therapeutics is held by insiders.Percentage Held by Institutions54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Perspective Therapeutics' insider trading history. Receive CATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CATX Stock News HeadlinesPerspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Rating of "Moderate Buy" from AnalystsAugust 18 at 2:44 AM | americanbankingnews.comBank of America Cuts Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $5.00August 17 at 2:12 AM | americanbankingnews.comSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing total outflows to 14 billion. At the same time, the World Gold Council recorded the highest quarterly central bank gold buying on record, with buyers taking physical delivery instead of paper shares.August 18 at 1:00 AM | Behind the Markets (Ad)Q3 EPS Estimate for Perspective Therapeutics Raised by AnalystAugust 16 at 2:01 AM | americanbankingnews.comBrokers Offer Predictions for Perspective Therapeutics Q1 EarningsAugust 15 at 2:13 AM | americanbankingnews.comPiper Sandler Has Lowered Expectations for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock PriceAugust 13, 2026 | americanbankingnews.comPerspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC SaysAugust 12, 2026 | finance.yahoo.comPerspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 ResultsAugust 10, 2026 | finance.yahoo.comSee More Headlines CATX Stock Analysis - Frequently Asked Questions How have CATX shares performed this year? Perspective Therapeutics' stock was trading at $2.75 at the start of the year. Since then, CATX shares have increased by 15.8% and is now trading at $3.1850. How were Perspective Therapeutics' earnings last quarter? Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) posted its earnings results on Monday, August, 10th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. The firm earned $0.08 million during the quarter, compared to analyst estimates of $0.09 million. Perspective Therapeutics had a negative trailing twelve-month return on equity of 41.92% and a negative net margin of 28,467.97%. When did Perspective Therapeutics' stock split? Shares of Perspective Therapeutics reverse split on the morning of Monday, June 17th 2024.The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Perspective Therapeutics' major shareholders? Top institutional shareholders of Perspective Therapeutics include Bank of New York Mellon Corp (0.26%), Portland Investment Counsel Inc. (0.22%) and Taylor & Morgan Wealth Management LLC (0.06%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Lori A Woods, Markus Puhlmann, Jonathan Robert Hunt, Johan M Spoor, Juan Graham, Heidi Henson and Robert F Williamson III. View institutional ownership trends. How do I buy shares of Perspective Therapeutics? Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/10/2026Today8/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 CATX's financial health is in the Yellow zone, according to TradeSmith. CATX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:CATX Previous SymbolNYSE:CATX CIK728387 Webwww.perspectivetherapeutics.com Phone206-676-0900Fax509-267-3670Employees70Year FoundedN/APrice Target and Rating Average Price Target for Perspective Therapeutics$11.56 High Price Target$14.00 Low Price Target$5.00 Potential Upside/Downside+262.8%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$103.12 million Net Margins-28,467.97% Pretax Margin-28,710.03% Return on Equity-41.92% Return on Assets-34.42% Debt Debt-to-Equity RatioN/A Current Ratio6.61 Quick Ratio6.61 Sales & Book Value Annual Sales$880 thousand Price / Sales413.15 Cash FlowN/A Price / Cash FlowN/A Book Value$2.79 per share Price / Book1.14Miscellaneous Outstanding Shares114,150,000Free Float110,739,000Market Cap$363.57 million OptionableOptionable Beta1.77 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NYSEAMERICAN:CATX) was last updated on 8/18/2026 by MarketBeat.com Staff. From Our PartnersSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...TradeSmith | SponsoredIran War: What Happened at 1:11 P.M. Outside D.C.?A source with ties to Saudi Arabia, the UAE, and the U.S. State Department revealed details of a potential 7 t...Banyan Hill Publishing | SponsoredElon's Terrifying Warning: America Is "1,000% Going Bankrupt"The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredSMX Could Turn Proof Technology into Major Profit!SMX (Security Matters) PLC embeds invisible molecular markers into materials like plastics, metals, fuels, and...Smallcaps Daily | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredGold Miners Post Record Cash Flow Even as Prices Pull BackThe four largest gold miners are generating record free cash flow, even with gold pulling back from recent hig...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
